CXCL1 confers a survival advantage in Kaposi's sarcoma‐associated herpesvirus‐infected human endothelial cells through STAT3 phosphorylation. Issue 1 (29th July 2022)
- Record Type:
- Journal Article
- Title:
- CXCL1 confers a survival advantage in Kaposi's sarcoma‐associated herpesvirus‐infected human endothelial cells through STAT3 phosphorylation. Issue 1 (29th July 2022)
- Main Title:
- CXCL1 confers a survival advantage in Kaposi's sarcoma‐associated herpesvirus‐infected human endothelial cells through STAT3 phosphorylation
- Authors:
- Lee, Myung‐Ju
Lee, Jisu
Kang, Su‐Kyung
Wirth, Dagmar
Yoo, Seung‐Min
Park, Changhoon
Lee, Myung‐Shin - Abstract:
- Abstract: Many cytokines produced by Kaposi's sarcoma‐associated herpesvirus (KSHV)‐infected cells have been shown to participate in the pathogenesis of KSHV. Determination of the exact role of cytokines in Kaposi's sarcoma (KS) pathogenesis is limited, however, by the difficulty to manipulate the target genes in human endothelial cells. In this study, we sought to elucidate the role of cytokines in KSHV‐infected human immortalized endothelial cell line (HuARLT cells) by knockout (KO) of the corresponding target genes using the CRISPR/Cas9 system. The cytokine production profile of KSHV‐infected HuARLT cells was analyzed using a protein array, and several cytokines were found to be highly upregulated following KSHV infection. This study focused on CXCL1, which was investigated by knocked out in HuARLT cells. KSHV‐infected CXCL1 KO cells underwent increased cell death compared to KSHV‐infected wild‐type (WT) cells and mock‐infected CXCL1 KO cells. Lytic replication was not observed in KSHV‐infected WT nor CXCL1 KO cells. Phosphorylation of STAT3 was significantly suppressed in KSHV‐infected CXCL1 KO cells. Additionally, inhibitors of STAT3 and CXCL1 induced cell death in KSHV‐infected endothelial cells. Our results show that CXCL1 production is required for the survival of KSHV‐infected endothelial cells, and the CXCL1 to STAT3 phosphorylation signaling pathway may be a therapeutic target for KS.
- Is Part Of:
- Journal of medical virology. Volume 95:Issue 1(2023)
- Journal:
- Journal of medical virology
- Issue:
- Volume 95:Issue 1(2023)
- Issue Display:
- Volume 95, Issue 1 (2023)
- Year:
- 2023
- Volume:
- 95
- Issue:
- 1
- Issue Sort Value:
- 2023-0095-0001-0000
- Page Start:
- n/a
- Page End:
- n/a
- Publication Date:
- 2022-07-29
- Subjects:
- CRISPR/Cas9 -- CXCL1 -- GRO‐α -- herpesvirus -- KSHV -- STAT3
Virology -- Periodicals
616 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1096-9071 ↗
http://www.interscience.wiley.com/jpages/0146-6615 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/jmv.28020 ↗
- Languages:
- English
- ISSNs:
- 0146-6615
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5017.095000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 25170.xml